This area of research in epilepsy aims to offer a therapy targeted to the molecular abnormality that is causing the patient’s symptoms. AGE program offers many such precision medicine clinical trials to the patients with severe drug resistance epilepsies often associated with intellectual disability, motor problems, and a higher mortality rate than other more common forms of epilepsy. Dr Andrade has created a Developmental and Epileptic Encephalopathy Registry in the province of Ontario, where 14 million people live. This DEE registry has patients trial-ready for precision medicine in genetic epilepsies.